Literature DB >> 23696113

[Integrated management of patients with chronic inflammatory bowel disease in the Rhine-Main Region: results of the first integrated health-care project IBD in Germany].

I Blumenstein1, W Tacke, N Filmann, C Zosel, H Bock, V Heuzeroth, S Zeuzem, O Schröder.   

Abstract

INTRODUCTION: In our previous studies investigating the drug therapy in patients suffering from inflammatory bowel disease (IBD) in the Rhein-Main region, Germany, we detected serious discrepancies between treatment reality and treatment guidelines. Consecutively, patient outcome in this cohort was compromised. Following this pilot project a network between primary deliverers of care for IBD patients and one large health-care insurance company [BKK Taunus (Gesundheit), the second largest insurance company in Hessen, Germany] was established. PATIENTS AND METHODS: An analysis of treatment and socioeconomic data from 220 IBD patients (Crohn's disease - CD = 96, ulcerative colitis - UC = 124) entering the integrative health-care programme between 1.1.-30.9.2009 was performed.
RESULTS: Remission rates for CD and UC in the integrated health-care programme could be improved from 60 - 73 % (CD) and from 61 - 79 % (UC). Guideline-conform treatment was observed in 81 % of patients with CD and 85 % with UC, respectively. Although medication costs increased, total costs could be cut by 162 304.- €, as secondary costs for hospitalisation and days off work could be reduced.
CONCLUSION: The study shows that networking of deliverers of care for IBD patients with health insurances provides an excellent possibility to optimise medical treatment and can cut down costs significantly. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 23696113     DOI: 10.1055/s-0032-1330572

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  3 in total

1.  Management of Crohn's disease - are guidelines transferred to clinical practice?

Authors:  Thomas Klag; Eduard F Stange; Jan Wehkamp
Journal:  United European Gastroenterol J       Date:  2015-08       Impact factor: 4.623

2.  Quality of care in inflammatory bowel disease: results of a prospective controlled cohort study in Germany (NETIBD).

Authors:  Jana Langbrandtner; Angelika Hüppe; Petra Jessen; Jürgen Büning; Susanna Nikolaus; Heiner Raspe; Bernd Bokemeyer
Journal:  Clin Exp Gastroenterol       Date:  2017-09-04

Review 3.  Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.

Authors:  Stephan Karl Böhm; Wolfgang Kruis
Journal:  Clin Exp Gastroenterol       Date:  2014-09-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.